Screener
TG Therapeutics TGTX EBIT
EBIT at other companies
Other financials
Where this comes from
Calculated from TG Therapeutics’s reported figures.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's EBIT?
- TG Therapeutics (TGTX) reported EBIT of $21.67M in Q2 2026.
- How has TG Therapeutics's EBIT changed year-over-year?
- TG Therapeutics's EBIT decreased by 37.8% year-over-year, from $34.84M to $21.67M.
- What is the long-term trend for TG Therapeutics's EBIT?
- Over 3 years (2021 to 2025), TG Therapeutics's EBIT has grown at a -29.0% compound annual growth rate (CAGR), from -$344.77M to $123.32M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about TG Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude